BiotechTube

SAF312 + Placebo to SAF312

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurogenic Urinary Bladder

Conditions

Neurogenic Urinary Bladder, Neurogenic Bladder Disorder, Neurogenic Dysfunction of the Urinary Bladder, Neurogenic Bladder, Uninhibited, Neurogenic Bladder, Spastic

Trial Timeline

Jan 1, 2012 → Sep 1, 2012

NCT ID
NCT01598103

About SAF312 + Placebo to SAF312

SAF312 + Placebo to SAF312 is a phase 2 stage product being developed by Novartis for Neurogenic Urinary Bladder. The current trial status is terminated. This product is registered under clinical trial identifier NCT01598103. Target conditions include Neurogenic Urinary Bladder, Neurogenic Bladder Disorder, Neurogenic Dysfunction of the Urinary Bladder.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01598103Phase 2Terminated

Competing Products

20 competing products in Neurogenic Urinary Bladder

See all competitors
ProductCompanyStageHype Score
MirabegronAstellas PharmaPhase 3
77
Solifenacin succinateAstellas PharmaPhase 3
77
Solifenacin succinateAstellas PharmaPhase 3
77
MirabegronAstellas PharmaPhase 1
33
mirabegronAstellas PharmaPhase 3
77
4 mg Fesoterodine ER tablet from Zwickau + 4 mg fesoterodine ER tablet from Freiburg + 8 mg fesoterodine ER tablet from Zwickau + 8 mg fesoterodine ER tablet from FreiburgPfizerPhase 1
32
Fesoterodine PR 4 mg + Fesoterodine PR 8 mg + Fesoterodine BIC 2 mg + Fesoterodine BIC 4 mgPfizerPhase 3
76
Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B) + Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B) + Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B) + Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A) + Fesoterodine BIC SR4 fed (Treatment E in Part B)PfizerPhase 1
32
Fesoterodine PR 4 mg + Fesoterodine PR 8 mg + Fesoterodine PR 8 mg + Oxybutynin + Fesoterodine PR + Fesoterodine BIC 2 mg + Fesoterodine BIC 4 mgPfizerPhase 3
76
alfuzosin (SL770499)SanofiPhase 3
76
Alfuzosin + PlaceboSanofiPhase 3
76
Droxidopa capsules + Placebo capsulesLundbeckApproved
82
Rec 0/0438 1 mg or Rec 0/0438 2 mg + placeboRecordatiPhase 1/2
38
Ampreloxetine + PlaceboTheravance BiopharmaPhase 3
72
ampreloxetine + PlaceboTheravance BiopharmaPhase 3
72
ampreloxetine + PlaceboTheravance BiopharmaPhase 3
72
TD-9855 + PlaceboTheravance BiopharmaPhase 2
47
ampreloxetineTheravance BiopharmaPhase 3
72
Ampreloxetine <Dose A> + Ampreloxetine <Dose B> + Ampreloxetine Placebo + Moxifloxacin + Moxifloxacin PlaceboTheravance BiopharmaPhase 1
28
AmpreloxetineTheravance BiopharmaPhase 1
28

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85